BlackRock
ENVB icon

BlackRock’s Enveric Biosciences ENVB Stock Holding History

BlackRock’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70 Hold
51
– – ﹤0.01% 5624
2026
Q1 		$99 Hold
51
– – ﹤0.01% 5611
2025
Q4 		$185 Buy
51
+1
+2% +$7 ﹤0.01% 5462
2025
Q3 		$384 Hold
50
– – ﹤0.01% 5376
2025
Q2 		$727 Hold
50
– – ﹤0.01% 5365
2025
Q1 		$835 Hold
50
– – ﹤0.01% 5337
2024
Q4 		$3.23K Hold
50
– – ﹤0.01% 5259
2024
Q3 		$4.27K Sell
50
-114
-70% -$10.5K ﹤0.01% 5054
2024
Q2 		$18.5K Hold
164
– – ﹤0.01% 5015
2024
Q1 		$29.6K Hold
164
– – ﹤0.01% 4971
2023
Q4 		$38.5K Hold
164
– – ﹤0.01% 5004
2023
Q3 		$70.4K Hold
164
– – ﹤0.01% 4932
2023
Q2 		$99.7K Hold
164
– – ﹤0.01% 4911
2023
Q1 		$49.2K Hold
164
– – ﹤0.01% 5121
2022
Q4 		$61.5K Hold
164
– – ﹤0.01% 5172
2022
Q3 		$125K Buy
164
+114
+228% +$144K ﹤0.01% 5105
2022
Q2 		$97K Sell
50
-5
-9% -$10.6K ﹤0.01% 5248
2022
Q1 		$165K Sell
55
-1
-2% -$4.42K ﹤0.01% 5155
2021
Q4 		$466K Hold
56
– – ﹤0.01% 4887
2021
Q3 		$1.04M Sell
56
-1
-2% -$19.4K ﹤0.01% 4541
2021
Q2 		$1.21M Sell
57
-6
-10% -$129K ﹤0.01% 4455
2021
Q1 		$1.73M Buy
+63
New +$2.2M ﹤0.01% 4330

Other funds holding ENVB

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

BlackRock's ENVB Position: Q2 2026 in Review

BlackRock held its Enveric Biosciences (ENVB) position steady in Q2 2026 at 51 shares worth $70. The position accounts for ﹤0.01% of the portfolio, ranked #5624.

BlackRock first reported a position in ENVB in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.73M in Q1 2021. 15 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • BlackRock held 51 shares of Enveric Biosciences worth $70 as of Q2 2026.
  • BlackRock left its Enveric Biosciences share count unchanged in Q2 2026.
  • Enveric Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5624 holding.
  • BlackRock first reported a position in Enveric Biosciences in Q1 2021 and has held it in 22 quarters since.
  • BlackRock's Enveric Biosciences position peaked at $1.73M in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.